Global life sciences company Malin Corporation has said that Dr Adrian Howd will cease to act as the company's chief executive from October 26. 

Dr Howd will also step down as a director of the company from today. 

Malin Corporation said that Ian Curley, who joined the board as non-executive Chairman on July 16, will become executive chairman on an interim basis, working closely with chief financial officer Darragh Lyons. 

The company said that Mr Curley will serve in that capacity until it has made "significant progress in its development, particularly in relation to its most significant assets and in continued cost reductions".

As previously announced, Malin's board is undertaking an extensive review of its portfolio and development strategy.

"Given the recent changes, now feels like a good time for me to part with Malin and embark on the next stage of my career," commented Dr Howd.

"I am proud of our assets and the prospects for our portfolio, especially the highest value, therapeutic investments, which currently account for approximately 70% of Malin's IPEV," he added.

Malin invests in high-growth opportunities in the global healthcare sector.